LegalView Adds New Content to Provide Users with Updated Information on the Trasylol HeartSurgery Drug Recall

Makers of the heart surgery drug, Trasylol, faced pressures from regulators around the world recently to halt sales of the controversial drug when a Canadian study indicated that the drug may actually contribute to increased death rates in users. Trasylol is used to reduce the risks of excessive bleeding to those receiving heart surgery. Bayer A.G.'s drug, Trasylol, also known as asprotinin, was also linked in a 2006 study in the New England Journal of Medicine as having increased risks for stroke, heart attack and kidney failure in patients. LegalView, your source for everything legal, immediately updated its site to host a detailed Trasylol information (


LegalView Adds New Content to Provide Users with Updated Information on the Trasylol HeartSurgery Drug Recall



***Note This page is an Archieve of Publicly released information either through our company or another Press Release organization. We do not "fact check", "Support", nor "Dispute" any of the information provided to us. We are a distribution point and Historical press release research and search service. This information only represents the fact that at one point in time the release was distributed to 1000's of publications both online and off. PRNewsNow will not take sides in any personal or commercial disputes you have with the writer of this press release. We will defend its right to exist blindly and without regards to its political, commercial or personal implications.***